Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 May 2024 to 31 May 2024 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council)
Date: 2024-06-28
Institutions: Directorate-General for Health and Food Safety, European Commission
Subjects: EU Member State, drug surveillance, market approval, marketing standard, medicinal product, veterinary medicinal product








C_202403877EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/3877


28.6.2024






Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 May 2024 to 31 May 2024
         


(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council
                (1)
or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council
                (2)
)


(C/2024/3877)







—



Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted













Date of the decision


Name of the medicinal product


INN (International Non-Proprietary Name)


Holder of the marketing authorisation


Number of the entry in the Community Register


Pharmaceutical form


ATC code (Anatomical Therapeutic Chemical Code)


Date of notification




16.5.2024


Jubbonti


denosumab







Sandoz GmbH




Biochemiestrasse 10, 6250 Kundl, Österreich






EU/1/24/1813


Solution for injection


M05BX04


21.5.2024




16.5.2024


Omlyclo


Omalizumab







Celltrion Healthcare Hungary Kft.




Váci út 1-3. WestEnd Office Building B torony, 1062 Budapest, Magyarország






EU/1/24/1817


Solution for injection in a pre-filled syringe


R03DX05


24.5.2024




17.5.2024


Awiqli


insulin icodec







Novo Nordisk A/S




Novo Alle 1, 2880 Bagsvaerd, Danmark






EU/1/24/1815


Solution for injection in pre-filled pen


A10AE07


21.5.2024




17.5.2024


FABHALTA


iptacopan







Novartis Europharm Limited




Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland






EU/1/24/1802


Capsule, hard


L04AJ08


21.5.2024




17.5.2024


Wyost


denosumab







Sandoz GmbH




Biochemiestrasse 10, 6250 Kundl, Österreich






EU/1/24/1812


Solution for injection


M05BX04


21.5.2024




27.5.2024


Lytenava


bevacizumab gamma







Outlook Therapeutics Limited




10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland






EU/1/24/1798


Solution for injection


S01LA08


28.5.2024




27.5.2024


Neoatricon


dopamine hydrochloride







BrePco Biopharma Ltd.




Suite One, The Avenue, Beacon Court, Sandyford, Dublin D18HX31, Ireland






EU/1/24/1804


Solution for infusion


C01CA04


28.5.2024




29.5.2024


Agilus


Dantrolene sodium hemiheptahydrate







Norgine B.V.




Antonio Vivaldistraat 150, 1083 HP Amsterdam, Nederland






EU/1/24/1805


Powder for solution for injection


M03CA01


30.5.2024




29.5.2024


Qalsody


tofersen







Biogen Netherlands B.V.




Prins Mauritslaan 13, 1171 LP Badhoevedorp, Nederland






EU/1/23/1783


Solution for injection


N07XX22


3.6.2024














—



Modification of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted










Date of the decision


Name of the medicinal product


Holder of the marketing authorisation


Number of the entry in the Community Register


Date of notification




6.5.2024


ASPAVELI







Swedish Orphan Biovitrum AB (publ)




112 76 Stockholm, Sverige






EU/1/21/1595


7.5.2024




6.5.2024


Circadin







RAD Neurim Pharmaceuticals EEC SARL




4 rue de Marivaux, 75002 Paris, France






EU/1/07/392


7.5.2024




6.5.2024


Eliquis







Bristol-Myers Squibb/Pfizer EEIG




Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland






EU/1/11/691


8.5.2024




6.5.2024


Epclusa







Gilead Sciences Ireland UC




Carrigtohill, County Cork, T45 DP77, Ireland






EU/1/16/1116


7.5.2024




6.5.2024


Fendrix







GlaxoSmithKline Biologicals S.A.




rue de l'Institut 89, 1330 Rixensart, Belgique






EU/1/04/299


8.5.2024




6.5.2024


Kanuma







Alexion Europe SAS




103-105 rue Anatole France, 92300 Levallois-Perret, France






EU/1/15/1033


7.5.2024




6.5.2024


Kisplyx







Eisai GmbH




Edmund-Rumpler-Strasse 3, 60549 Frankfurt am Main, Deutschland






EU/1/16/1128


7.5.2024




6.5.2024


Orphacol







THERAVIA




16 Rue Montrosier, 92200 Neuilly-sur-Seine, France






EU/1/13/870


14.5.2024




6.5.2024


VEGZELMA







Celltrion Healthcare Hungary Kft.




Váci út 1-3. WestEnd Office Building B torony, 1062 Budapest, Magyarország






EU/1/22/1667


7.5.2024




6.5.2024


Xenical







CHEPLAPHARM Arzneimittel GmbH




Ziegelhof 24, 17489 Greifswald, Deutschland






EU/1/98/071


8.5.2024




10.5.2024


Armisarte







Actavis Group PTC ehf.




Dalshraun 1, 220 Hafnarfjörður, Íceland






EU/1/15/1063


13.5.2024




10.5.2024


Darunavir Mylan







Mylan Pharmaceuticals Limited




Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland






EU/1/16/1140


13.5.2024




10.5.2024


Fingolimod Accord







Accord Healthcare S.L.U.




World Trade Center, Moll de Barcelona, s/n, Edifici Est 6a planta, 08039 Barcelona, España






EU/1/20/1450


13.5.2024




10.5.2024


Lojuxta







Amryt Pharmaceuticals DAC




45 Mespil Road, Dublin 4, Ireland






EU/1/13/851


15.5.2024




10.5.2024


Nilemdo







Daiichi Sankyo Europe GmbH




Zielstattstraße 48, 81379 München, Deutschland






EU/1/20/1425


13.5.2024




10.5.2024


Nustendi







Daiichi Sankyo Europe GmbH




Zielstattstraße 48, 81379 München, Deutschland






EU/1/20/1424


14.5.2024




10.5.2024


PreHevbri







VBI Vaccines B.V.




Delflandlaan 1, Queen’s Tower Office Number 714, 1062 EA Amsterdam, Nederland






EU/1/22/1641


15.5.2024




10.5.2024


QUVIVIQ







Idorsia Pharmaceuticals Deutschland GmbH




Marie-Curie-Strasse 8, 79539 Loerrach, Deutschland






EU/1/22/1638


14.5.2024




10.5.2024


Revolade







Novartis Europharm Limited




Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland






EU/1/10/612


13.5.2024




10.5.2024


Thalidomide Lipomed







Lipomed GmbH




Hegenheimer Straße 2, 79576 Weil/Rhein, Deutschland






EU/1/22/1676


13.5.2024




10.5.2024


Thyrogen







Sanofi B.V.




Paasheuvelweg 25, 1105 BP Amsterdam, Nederland






EU/1/99/122


14.5.2024




10.5.2024


Trevicta







Janssen-Cilag International NV




Turnhoutseweg 30, 2340 Beerse, België






EU/1/14/971


14.5.2024




10.5.2024


Tyverb







Novartis Europharm Limited




Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland






EU/1/07/440


14.5.2024




15.5.2024


Comirnaty







BioNTech Manufacturing GmbH




An der Goldgrube 12, 55131 Mainz, Deutschland






EU/1/20/1528


16.5.2024




16.5.2024


AMGEVITA







Amgen Europe B.V.




Minervum 7061, 4817 ZK Breda, Nederland






EU/1/16/1164


17.5.2024




16.5.2024


Bondronat







Atnahs Pharma Netherlands B.V.




Copenhagen Towers, Ørestads Boulevard 108, 5.tv, DK-2300 København S, Danmark






EU/1/96/012


17.5.2024




16.5.2024


Cufence







Univar Solutions B.V.




Schouwburgplein 30, Rotterdam, 3012 CL, Nederland






EU/1/19/1365


21.5.2024




16.5.2024


Giapreza







PAION Deutschland GmbH




Heussstraße 25, 52078 Aachen, Deutschland






EU/1/19/1384


17.5.2024




16.5.2024


IBRANCE







Pfizer Europe MA EEIG




Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/ Pleinlaan 17, 1050 Brussel, België






EU/1/16/1147


17.5.2024




16.5.2024


Imvanex







Bavarian Nordic A/S




Philip Heymans Allé 3, DK-2900 Hellerup, Danmark






EU/1/13/855


30.5.2024




16.5.2024


Lumykras







Amgen Europe B.V.




Minervum 7061, 4817 ZK Breda, Nederland






EU/1/21/1603


17.5.2024




16.5.2024


NUBEQA







Bayer AG




D-51368 Leverkusen, Deutschland






EU/1/20/1432


17.5.2024




16.5.2024


PecFent







Grünenthal GmbH




Zieglerstraße 6, 52078, Aachen, Deutschland






EU/1/10/644


22.5.2024




16.5.2024


Rinvoq







AbbVie Deutschland GmbH & Co. KG




Knollstrasse, 67061 Ludwigshafen, Deutschland






EU/1/19/1404


17.5.2024




16.5.2024


Rozlytrek







Roche Registration GmbH




Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Deutschland






EU/1/20/1460


17.5.2024




16.5.2024


Rybrevant







Janssen-Cilag International NV




Turnhoutseweg 30, 2340 Beerse, België






EU/1/21/1594


17.5.2024




16.5.2024


Saphnelo







AstraZeneca AB




151 85 Södertälje, Sverige






EU/1/21/1623


17.5.2024




16.5.2024


Vipidia







Takeda Pharma A/S




Delta Park 45, 2665 Vallensbaek Strand, Danmark






EU/1/13/844


21.5.2024




16.5.2024


Xromi







Nova Laboratories Ireland Limited




3rd Floor, Ulysses House, Foley Street, Dublin 1, D01 W2T2, Ireland






EU/1/19/1366


20.5.2024




17.5.2024


Grasustek







Juta Pharma GmbH




Gutenbergstr. 13, 24941, Flensburg, Deutschland






EU/1/19/1375


23.5.2024




17.5.2024


Levetiracetam Actavis







Actavis Group PTC ehf.




Dalshraun 1, 220 Hafnarfjörður, Íceland






EU/1/11/713


21.5.2024




17.5.2024


Methylthioninium chloride Proveblue







Provepharm S.A.S.




22 rue Marc Donadille, 13013 Marseille, France






EU/1/11/682


22.5.2024




17.5.2024


NUCEIVA







Evolus Pharma B.V.




Apollolaan 151, 1077 AR Amsterdam, Nederland






EU/1/19/1364


21.5.2024




17.5.2024


Oxbryta







Pfizer Europe MA EEIG




Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/ Pleinlaan 17, 1050 Brussel, België






EU/1/21/1622


21.5.2024




17.5.2024


Qdenga







Takeda GmbH




Byk-Gulden-Straße 2, 78467 Konstanz, Deutschland






EU/1/22/1699


21.5.2024




17.5.2024


TRISENOX







Teva B.V.




Swensweg 5, 2031 GA Haarlem, Nederland






EU/1/02/204


22.5.2024




21.5.2024


Rivaroxaban Accord







Accord Healthcare S.L.U.




World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, 08039 Barcelona, España






EU/1/20/1488


22.5.2024




22.5.2024


BEKEMV







Amgen Technology (Ireland) UC




Pottery Road, Dun Laoghaire, Co. Dublin, Ireland






EU/1/23/1727


24.5.2024




22.5.2024


BiResp Spiromax







Teva Pharma B.V.




Swensweg 5, 2031GA Haarlem, Nederland






EU/1/14/921


28.5.2024




22.5.2024


Bosulif







Pfizer Europe MA EEIG




Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/ Pleinlaan 17, 1050 Brussel, België






EU/1/13/818


23.5.2024




22.5.2024


Buccolam







Neuraxpharm Pharmaceuticals, S.L.




Avda. Barcelona 69, 08970 Sant Joan Despí - Barcelona, España






EU/1/11/709


24.5.2024




22.5.2024


DuoResp Spiromax







Teva Pharma B.V.




Swensweg 5, 2031GA Haarlem, Nederland






EU/1/14/920


28.5.2024




22.5.2024


Ebilfumin







Actavis Group PTC ehf.




Dalshraun 1, 220 Hafnarfjörður, Íceland






EU/1/14/915


23.5.2024




22.5.2024


Eptifibatide Accord







Accord Healthcare S.L.U.




World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, 08039 Barcelona, España






EU/1/15/1065


23.5.2024




22.5.2024


EVOTAZ







Bristol-Myers Squibb Pharma EEIG




Plaza 254, Blanchardstown Corporate Park 2, D15 T867, Dublin 15, Ireland






EU/1/15/1025


23.5.2024




22.5.2024


Karvezide







Sanofi Winthrop Industrie




82 avenue Raspail, 94250 Gentilly, France






EU/1/98/085


24.5.2024




22.5.2024


Komboglyze







AstraZeneca AB




151 85 Södertälje, Sverige






EU/1/11/731


24.5.2024




22.5.2024


Lytgobi







Taiho Pharma Netherlands B.V.




Barbara Strozzilaan 201, 1083 HN Amsterdam, Noord-Holland, Nederland






EU/1/23/1741


29.5.2024




22.5.2024


Menveo







GSK Vaccines S.r.l.




Via Fiorentina 1, 53100 Siena, Italia






EU/1/10/614


27.5.2024




22.5.2024


Opzelura







Incyte Biosciences Distribution B.V.




Paasheuvelweg 25, 1105 BP Amsterdam, Nederland






EU/1/23/1726


23.5.2024




22.5.2024


Procysbi







Chiesi Farmaceutici S.p.A.




Via Palermo 26/A, 43122 Parma, Italia






EU/1/13/861


29.5.2024




22.5.2024


Ratiograstim







ratiopharm GmbH




Graf-Arco-Straße 3, 89079 Ulm, Deutschland






EU/1/08/444


3.6.2024




22.5.2024


Sialanar







Proveca Pharma Limited




2 Dublin Landings, North Wall Quay, Dublin 1, Ireland






EU/1/16/1135


23.5.2024




23.5.2024


Evrenzo







Astellas Pharma Europe B.V.




Sylviusweg 62, 2333 BE Leiden, Nederland






EU/1/21/1574


23.5.2024




23.5.2024


Levetiracetam ratiopharm







ratiopharm GmbH




Graf-Arco-Straße 3, 89079 Ulm, Deutschland






EU/1/11/702


28.5.2024




23.5.2024


Levetiracetam Teva







Teva B.V.




Swensweg 5, 2031 GA Haarlem, Nederland






EU/1/11/701


23.5.2024




23.5.2024


OPDIVO







Bristol-Myers Squibb Pharma EEIG




Plaza 254, Blanchardstown Corporate Park 2, D15 T867, Dublin 15, Ireland






EU/1/15/1014


23.5.2024




27.5.2024


Aimovig







Novartis Europharm Limited




Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland






EU/1/18/1293


28.5.2024




27.5.2024


Camcevi







Accord Healthcare S.L.U.




World Trade Center, Moll de Barcelona, s/n, Edifici Est 6a planta, 08039 Barcelona, España






EU/1/22/1647


28.5.2024




27.5.2024


Columvi







Roche Registration GmbH




Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Deutschland






EU/1/23/1742


28.5.2024




27.5.2024


Imfinzi







AstraZeneca AB




151 85 Södertälje, Sverige






EU/1/18/1322


28.5.2024




27.5.2024


IMJUDO







AstraZeneca AB




151 85 Södertälje, Sverige






EU/1/22/1713


28.5.2024




27.5.2024


Reyataz







Bristol-Myers Squibb Pharma EEIG




Plaza 254, Blanchardstown Corporate Park 2, D15 T867, Dublin 15, Ireland






EU/1/03/267


28.5.2024




27.5.2024


Triumeq







ViiV Healthcare BV




Van Asch van Wijckstraat 55H, 3811 LP Amersfoort, Nederland






EU/1/14/940


28.5.2024




29.5.2024


BLINCYTO







Amgen Europe B.V.




Minervum 7061, 4817 ZK Breda, Nederland






EU/1/15/1047


26.4.2024




29.5.2024


BLINCYTO







Amgen Europe B.V.




Minervum 7061, 4817 ZK Breda, Nederland






EU/1/15/1047


30.5.2024




29.5.2024


Cerdelga







Sanofi B.V.




Paasheuvelweg 25, 1105 BP Amsterdam, Nederland






EU/1/14/974


31.5.2024




29.5.2024


Desloratadine Actavis







Actavis Group PTC ehf.




Dalshraun 1, 220 Hafnarfjörður, Íceland






EU/1/11/745


1.6.2024




29.5.2024


Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva







Zentiva, k.s.




U Kabelovny 130, 102 37 Praha 10, Česká republika






EU/1/17/1210


30.5.2024




29.5.2024


Emtricitabine/Tenofovir disoproxil Krka







KRKA d d., Novo mesto




Šmarješka cesta 6, 8501 Novo mesto, Slovenija






EU/1/16/1151


30.5.2024




29.5.2024


Emtricitabine /Tenofovir disoproxil Krka d.d.







KRKA d d., Novo mesto




Šmarješka cesta 6, 8501 Novo mesto, Slovenija






EU/1/17/1182


6.6.2024




29.5.2024


Myocet liposomal







CHEPLAPHARM Arzneimittel GmbH




Ziegelhof 24, 17489 Greifswald, Deutschland






EU/1/00/141


3.6.2024




29.5.2024


Omidria







Rayner Surgical (Ireland) Limited




The Mill Enterprise Hub, Newtown Link Road, Drogheda, A92 CD3D, Co. Louth, Ireland






EU/1/15/1018


4.6.2024




29.5.2024


Pregabalin Sandoz







Sandoz GmbH




Biochemiestrasse 10, 6250 Kundl, Österreich






EU/1/15/1011


6.6.2024














—



Issuing of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council): Accepted













Date of the decision


Name of the medicinal product


INN (International Non-Proprietary Name)


Holder of the marketing authorisation


Number of the entry in the Community Register


Pharmaceutical form


ATC code (Anatomical Therapeutic Chemical Code)


Date of notification




6.5.2024


Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS


Avian metapneumovirus, avian infectious bronchitis, Newcastle disease, avian infectious bursal disease, avian reovirus and egg drop syndrome virus vaccine (inactivated)







Intervet International B.V.




Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland






EU/2/24/309


Emulsion for injection


QI01AA24


8.5.2024




6.5.2024


Trilocur


trilostane







Emdoka




John Lijsenstraat 16, 2321 Hoogstraten, België






EU/2/24/312


Oral suspension


QH02CA01


7.5.2024




6.5.2024


Trilorale


trilostane







Axience




Tour Essor, 14 Rue Scandicci, 93500 Pantin, France






EU/2/24/313


Oral suspension


QH02CA01


7.5.2024




10.5.2024


DIVENCE Tetra


Bovine viral diarrhoea virus type 1 and type 2 (subunit, recombinant), bovine parainfluenza 3 virus (inactivated) and bovine respiratory syncytial virus (live) vaccine







Laboratorios Hipra, S.A.




Avda. La Selva, 135, 17170 Amer (Girona), España






EU/2/24/310


Lyophilisate and solvent for solution for injection


Pending


13.5.2024




22.5.2024


Innovax-ND-H5


Newcastle disease, avian influenza and Marek's disease vaccine (live recombinant)







Intervet International B.V.




Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland






EU/2/24/315


Concentrate and solvent for suspension for injection


QI01AD


23.5.2024




30.5.2024


RESPIVAC TRT


Turkey rhinotracheitis virus, live







Laboratorios Hipra, S.A.




Avda. La Selva, 135, 17170 Amer (Girona), España






EU/2/24/314


Lyophilisate for suspension


QI01AD01


3.6.2024














—



Modification of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council): Accepted










Date of the decision


Name of the medicinal product


Holder of the marketing authorisation


Number of the entry in the Community Register


Date of notification




6.5.2024


Purevax RCP FeLV







Boehringer Ingelheim Vetmedica GmbH




D-55216 Ingelheim am Rhein, Deutschland






EU/2/04/048


8.5.2024




6.5.2024


RESPIPORC FLUpan H1N1







Ceva Santé Animale




10 avenue de La Ballastière, 33500 Libourne, France






EU/2/17/209


13.5.2024




6.5.2024


Suiseng Diff/A







Laboratorios Hipra, S.A.




Avda. La Selva, 135, 17170 Amer (Girona), España






EU/2/21/278


7.5.2024




6.5.2024


Zulvac BTV







Zoetis Belgium




rue Laid Burniat 1, 1348 Louvain-la-Neuve, Belgique






EU/2/17/207


8.5.2024




10.5.2024


ProZinc







Boehringer Ingelheim Vetmedica GmbH




55216 Ingelheim am Rhein, Deutschland






EU/2/13/152


14.5.2024




30.5.2024


Advocate







Elanco Animal Health GmbH




Alfred-Nobel-Str. 50, 40789 Monheim, Deutschland






EU/2/03/039


3.6.2024




30.5.2024


Convenia







Zoetis Belgium




rue Laid Burniat 1, 1348 Louvain-la-Neuve, Belgique






EU/2/06/059


3.6.2024




30.5.2024


Cortavance







VIRBAC S.A.




1ère Avenue - 2065 m - L.I.D., 06516 Carros CEDEX, France






EU/2/06/069


31.5.2024




30.5.2024


MS-H vaccine







Pharmsure Veterinary Products Europe Limited




4 Fitzwilliam Terrace, Strand Road, Bray, WICKLOW A98 T6H6, Ireland






EU/2/11/126


31.5.2024




30.5.2024


NEOLEISH







CZ Vaccines S.A.U.




A Relva s/n – Torneiros 36410 O Porriño Pontevedra, España






EU/2/22/290


3.6.2024




30.5.2024


NexGard







Boehringer Ingelheim Vetmedica GmbH




55216 Ingelheim am Rhein, Deutschland






EU/2/13/159


31.5.2024




30.5.2024


Syvazul BTV







Laboratorios Syva S.A




C/Marqués de la Ensenada16, 28004 Madrid, España






EU/2/18/231


3.6.2024




30.5.2024


UpCard







Vétoquinol SA




Magny-Vernois, 70200 Lure, France






EU/2/15/184


4.6.2024














—



Suspension of a marketing authorisation (Article 45 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council)









Date of the decision


Name of the medicinal product


Holder of the marketing authorisation


Number of the entry in the Community Register


Date of notification




15.5.2024


Kexxtone







Elanco GmbH




Heinz-Lohmann-Straße 4, 27472 Cuxhaven, Deutschland






EU/2/12/145


17.5.2024








Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:





European Medicines Agency




Domenico Scarlattilaan 6




1083 HS Amsterdam




NETHERLANDS






(1)  
            OJ L 136, 30.4.2004, p. 1.

(2)  
            OJ L 4, 7.1.2019, p. 43.


ELI: http://data.europa.eu/eli/C/2024/3877/oj
ISSN 1977-091X (electronic edition)